Last reviewed · How we verify
NCT06029608
Evaluation of the Efficacy and Safety of Magnetically-controlled Capsule Gastroscopy for Postoperative Assessment in Elderly Patients and Patients With Underlying Diseases
trial in Evaluation,Efficacy,Safety in 120 participants. Not yet recruiting.
30 May 2026
Quick facts
| Lead sponsor | Shanghai Jiao Tong University School of Medicine |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 6 November 2025 |
| Primary completion | 30 May 2026 |
| Estimated completion | 30 October 2026 |
| Sites | 1 location across China |
Conditions studied
- Evaluation,Efficacy,Safety — all drugs for Evaluation,Efficacy,Safety →
Sponsor
Shanghai Jiao Tong University School of Medicine
Who can join
18 and older, any sex, with Evaluation,Efficacy,Safety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this prospective, observational, controlled clinical study is to use magnetically-controlled capsule gastroscopy for postoperative assessment in elderly patients and patients with underlying diseases, to evaluate its clinical efficacy and safety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06029608
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Jiao Tong University School of Medicine trials
Trials by the same sponsor.
- NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
- NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
- NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
- NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
- NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06029608 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
- Last refreshed: 2 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06029608.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing